Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Sintilimab for ESCC Liver Metastasis
NCT06184841Phase 1Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Adverse Events up to 2 years. Started Jun 2020; status: completed.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06184841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184841.